April 22, 2020
2 min read

Rockwell Medical appoints new president, CEO with first-quarter earnings update to follow

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Russell H. Ellison

Rockwell Medical Inc., a company focused on developing treatments for kidney disease and anemia management, has appointed Russell H. Ellison, MD, MSc, as its new president and CEO, according to a company press release. Ellison will step into his new role “immediately,” while continuing to serve as a member of the company’s board.

According to the release, Ellison attended the London School of Tropical Medicine and Hygiene and the University of British Columbia, where he received a Master of Science and an MD, respectively. His previous experience includes serving on the board of directors for Cougar Biotechnology Inc., ProSanos Corporation and the “cardio-renal stage clinical company” Cormedix Inc.

Commending previous president and CEO, Stuart Paul for his work in launching Dialysate Triferic — currently the only FDA approved therapy in the United States “indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment,” according to the release — John P. McLaughlin, chair of the company’s board, weighed in on what makes Ellison a strong choice to fill the position.

“Russell’s extensive medical expertise, deep understanding of the renal and anemia space based on his experience developing therapeutic products, experience as a CEO of public and private companies, and capital markets knowledge make him an ideal candidate to drive our strategic direction,” he said in the release.

Of his own background with the company, Ellison said, “Through my work to date with Rockwell Medical as a consultant and a member of the board, I have gained an increased appreciation for the unique medical attributes of Triferic and the various opportunities we have to help patients with iron deficiency and create value for Rockwell Medical shareholders.”

He added, “I am honored to lead the company and look forward to continuing to work with my colleagues and other Rockwell Medical stakeholders to advance and deliver on the company’s strategy.”

The release further noted the company will be hosting a conference call and audio webcast on May 11 at 4:30 p.m. ET to discuss first-quarter financial results from 2020, while also providing a business update.